Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011.[1] Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.[2]
Mechanism of action
Faldaprevir is a hepatitis C virus protease inhibitor.[citation needed]
Studies
Faldaprevir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including deleobuvir.[citation needed]
Data from the SOUND-C2 study, presented at the 2012 AASLD Liver Meeting, showed that a triple combination of faldaprevir, deleobuvir, and ribavirin performed well in HCV genotype 1b patients.[3]
References
- ^ Clinical trial number NCT01343888 for "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)" at ClinicalTrials.gov
- ^ "Hepatitis C: Aus für Boehringers Faldaprevir". www.pharmazeutische-zeitung.de.
- ^ Kanda T, Yokosuka O, Omata M (March 2015). "Faldaprevir for the treatment of hepatitis C". International Journal of Molecular Sciences. 16 (3): 4985–96. doi:10.3390/ijms16034985. PMC 4394460. PMID 25749475.